Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/39947| Title: | Biologics for the treatment of autoimmune renal diseases. | Authors: | Holdsworth S.R. ;Gan P.-Y.;Kitching A.R. | Institution: | (Holdsworth, Gan, Kitching) Department of Medicine, Centre for Inflammatory Diseases, Monash University, Monash, VIC 3800, Australia (Holdsworth, Kitching) Department of Nephrology, Monash Health, 246 Clayton Road, Clayton, Melbourne, VIC 3168, Australia | Issue Date: | 11-Mar-2016 | Copyright year: | 2016 | Publisher: | Nature Publishing Group (Houndmills, Basingstoke, Hampshire RG21 6XS, United Kingdom) | Place of publication: | United Kingdom | Publication information: | Nature Reviews Nephrology. 12 (4) (pp 217-231), 2016. Date of Publication: 01 Apr 2016. | Journal: | Nature Reviews Nephrology | Abstract: | Biological therapeutics (biologics) that target autoimmune responses and inflammatory injury pathways have a marked beneficial impact on the management of many chronic diseases, including rheumatoid arthritis, psoriasis, inflammatory bowel disease, and ankylosing spondylitis. Accumulating data suggest that a growing number of renal diseases result from autoimmune injury-including lupus nephritis, IgA nephropathy, anti-neutrophil cytoplasmic antibody-associated glomerulonephritis, autoimmune (formerly idiopathic) membranous nephropathy, anti-glomerular basement membrane glomerulonephritis, and C3 nephropathy-and one can speculate that biologics might also be applicable to these diseases. As many autoimmune renal diseases are relatively uncommon, with long natural histories and diverse outcomes, clinical trials that aim to validate potentially useful biologics are difficult to design and/or perform. Some excellent consortia are undertaking cohort studies and clinical trials, but more multicentre international collaborations are needed to advance the introduction of new biologics to patients with autoimmune renal disorders. This Review discusses the key molecules that direct injurious inflammation and the biologics that are available to modulate them. The opportunities and challenges for the introduction of relevant biologics into treatment protocols for autoimmune renal diseases are also discussed.Copyright © 2016 Macmillan Publishers Limited. | DOI: | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1038/nrneph.2016.18 | PubMed URL: | 26949177 [http://www.ncbi.nlm.nih.gov/pubmed/?term=26949177] | ISSN: | 1759-5061 | URI: | https://repository.monashhealth.org/monashhealthjspui/handle/1/39947 | Type: | Article | Subjects: | phase 4 clinical trial (topic) priority journal protein targeting randomized controlled trial (topic) T lymphocyte activation abatacept/dt [Drug Therapy] adalimumab/dt [Drug Therapy] alemtuzumab/dt [Drug Therapy] atacicept/dt [Drug Therapy] basiliximab/dt [Drug Therapy] belatacept/dt [Drug Therapy] belimumab/dt [Drug Therapy] *biological product/dt [Drug Therapy] blisibimod/dt [Drug Therapy] canakinumab/dt [Drug Therapy] certolizumab pegol/dt [Drug Therapy] efalizumab/dt [Drug Therapy] epratuzumab/dt [Drug Therapy] etanercept/dt [Drug Therapy] golimumab/dt [Drug Therapy] infliximab/dt [Drug Therapy] milatuzumab/dt [Drug Therapy] obinutuzumab/dt [Drug Therapy] ocrelizumab/dt [Drug Therapy] ofatumumab/dt [Drug Therapy] OKT 3/dt [Drug Therapy] recombinant interleukin 1 receptor blocking agent/dt [Drug Therapy] rituximab/dt [Drug Therapy] rontalizumab/dt [Drug Therapy] secukinumab/dt [Drug Therapy] sifalimumab/dt [Drug Therapy] sirukumab/dt [Drug Therapy] tocilizumab/dt [Drug Therapy] unindexed drug veltuzumab/dt [Drug Therapy] membranous glomerulonephritis ANCA associated vasculitis article *autoimmune disease/dt [Drug Therapy] autoimmune disease/dt [Drug Therapy] autoimmunity B lymphocyte human humoral immunity *kidney disease/dt [Drug Therapy] kidney disease/dt [Drug Therapy] lupus erythematosus nephritis lymphocyte differentiation nonhuman phase 2 clinical trial (topic) phase 3 clinical trial (topic) nonhuman phase 2 clinical trial (topic) phase 3 clinical trial (topic) phase 4 clinical trial (topic) priority journal protein targeting randomized controlled trial (topic) T lymphocyte activation autoimmunity *autoimmune disease / *drug therapy Article ANCA associated vasculitis autoimmune disease / drug therapy B lymphocyte human humoral immunity *kidney disease / *drug therapy kidney disease / drug therapy lupus erythematosus nephritis lymphocyte differentiation membranous glomerulonephritis |
| Appears in Collections: | Articles |
Show full item record
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.